Press Release May 13, 2022

Ionpath Receives Strategic Investment To Support Spatial Proteomics Innovation

The Life Sciences team advised Ionpath, Inc. on its strategic investment by Thermo Fisher Scientific.

Ionpath, Inc., based in Menlo Park, California, is a pioneer in high-definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate medical discovery and improve human health. With its MIBI technology and the expertise of world-class pathology and data science teams, Ionpath provides actionable insights to translational and clinical researchers at leading pharmaceutical, biotechnology, and research organizations in immuno-oncology, immunology, neuroscience, and infectious disease research.

Thermo Fisher Scientific (NYSE: TMO), headquartered in Waltham, Massachusetts, is a global provider of medical equipment, analytical instruments, reagents and consumables, software and services to tackle complex analytical challenges in research, diagnostics and clinical laboratories, with annual revenue of approximately $40 billion. 

The Goodwin team was led by Richard Hoffman, Adam Small, Shoaib Ghias and Steve Argentieri. Goodwin has represented Ionpath since its early stage, including in its Series A and Series B preferred stock financings.

For more details, read the press release and article in GenomeWeb.